Open AccessS145: THE COMBINATION OF IBRUTINIB PLUS VENETOCLAX RESULTS IN A HIGH RATE OF MRD NEGATIVITY IN PREVIOUSLY UNTREATED CLL: THE RESULTS OF THE PLANNED INTERIM ANALYSIS OF THE PHASE III NCRI FLAIR TRIAL
Author(s) -
Hillmen P.,
Pitchford A.,
Bloor A.,
Pettitt A.,
Patten P.,
Forconi F.,
Schuh A.,
Fox C.,
Elmusharaf N.,
Gatto S.,
Kennedy B.,
Gribben J.,
Pemberton N.,
Sheehy O.,
Preston G.,
Howard D.,
Hockaday A.,
Cairns D.,
Jackson S.,
Greatorex N.,
Webster N.,
Dalal S.,
Shingles J.,
Cwynarski K.,
Paneesha S.,
Allsup D.,
Rawstron A.,
Munir T.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000843472.57904.29
Subject(s) - medicine , ibrutinib , minimal residual disease , venetoclax , neutropenia , oncology , gastroenterology , leukemia , chemotherapy , chronic lymphocytic leukemia